- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02774551
Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength
Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength in Esophageal Cancer Survivors
This intervention study will be conducted on patients included in a nationwide and prospective cohort, The Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR). The OSCAR includes patients operated on for oesophageal cancer in Sweden between 2013-2018, identified through pathology departments and included in the cohort 1 year after surgery. A comprehensive interview is conducted by a research nurse during a home visit using patient reported outcomes on several HRQOL, psychosocial, emotional and nutritional aspects. Regular follow-ups are carried out at 1½, 2, 2½, 3, 4 and 5 years postoperatively.
All patients within OSCAR are invited to the intervention trial. Half of the eligible patients will be randomised to intervention and half to standard care (control group) by means of block randomisation method. The intervention group will be encouraged to adhere to a physical activity regimen of 150 minutes of weekly minimum intensity activities and 5 simple strength training exercises twice a week as instructed by the research nurse. The control group will follow their routine daily physical activity. HRQOL measures, height and weight, body composition, muscle strength, functional mobility and strength, and dietary intake are assessed before and after the intervention. Compliance will be ensured by means of a daily physical activity dairy and a weekly follow up on telephone with all patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Surgical cares sciences, Karolinksa Institutet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients from the nationwide prospective cohort the Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR) with willingness to participate
Exclusion Criteria:
- Current malignancies or co-morbidities, psychological or social conditions that prevent participation
- Patients with pacemakers; cochlear or other electrical implants cannot be screened using the bio-impedance scale for safety reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Physical activity intervention group
The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g.
walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse.
The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
|
150 minutes of minimum intensity activity during a week (e.g.
walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
|
|
No Intervention: Standard care control group
Patients follow their routine daily physical activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment related increase in muscle mass as assessed by a bio-impedance body composition scale.
Time Frame: At baseline and after the 12 weeks intervention/control programme.
|
The main outcome measure will be increase in skeletal muscle mass using a bio-impedance analysis portable monitor.
Changes occurring during the period just before and just after the 12-weeks intervention programme, or standard of care in the comparison group, will be compared between the intervention group.
|
At baseline and after the 12 weeks intervention/control programme.
|
|
Number of participants with treatment related increase in muscle strength as assessed by a hand grip dynamometer and chair stand test.
Time Frame: At baseline and after the 12 weeks intervention/control programme.
|
The main outcome measure will be increase in skeletal muscle strength using a handgrip dynamometer and 30 second sit stand test.
Changes occurring during the period just before and just after the 12-weeks intervention programme, or standard of care in the comparison group, will be compared between the intervention group.
|
At baseline and after the 12 weeks intervention/control programme.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with improvement in physical function scale of health related quality of life as assessed from the questionnaire - European Organization for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) - C30.
Time Frame: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the physical function scale of HRQOL using EORTC QLQ-C30 questionnaires before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
|
Number of participants with improvement in fatigue scale of health related quality of life as assessed from the questionnaire - EORTC QLQ-FA13.
Time Frame: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the fatigue scale of HRQOL using EORTC fatigue questionnaire QLQ-FA13 before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
|
Number of participants with improvement in appetite loss function of health related quality of life as assessed from the oesophageal disease specific module - EORTC QLQ-OG25.
Time Frame: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the appetite loss function of HRQOL using EORTC QLQ-OG25 questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
|
Number of participants with improvement in eating difficulties scale of health related quality of life as assessed from the cachexia module of EORTC - QLQ-CAX24.
Time Frame: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the eating difficulties scale of HRQOL using EORTC QLQ-CAX24 questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
|
Number of participants with improvement in psycho social issues as assessed from the questionnaire - Hospital Anxiety and Depression Scale (HADS).
Time Frame: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the psychosocial issues using HADS questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
|
Number of participants with improvement in physical activity level measured using the international physical activity questionnaire (IPAQ).
Time Frame: At baseline and after the 12 weeks intervention/control programme.
|
This secondary outcome shall include changes in the total physical activity level measured using the international physical activity questionnaire (IPAQ) before and after the intervention.
|
At baseline and after the 12 weeks intervention/control programme.
|
|
Number of participants with improvement in dietary intake measured using 3 day food diary.
Time Frame: Just before (baseline) and just after (final follow up) the 12 weeks intervention programme.
|
This secondary outcome shall include changes in dietary intake measured using food dairy measured thrice a week: two weekdays and 1 weekend day before and after the intervention.
|
Just before (baseline) and just after (final follow up) the 12 weeks intervention programme.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pernilla Lagergren, Professor, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PA study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oesophageal Cancer
-
Launceston General HospitalNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruitingSquamous Oesophageal CancerChina
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation TrustCompletedOesophageal AdenocarcinomaUnited Kingdom
-
Royal Marsden NHS Foundation TrustAstraZenecaUnknownGastric Cancer | Oesophageal Cancer | Gastro-Oesophageal Junction CancerUnited Kingdom
-
Imperial College LondonNot yet recruitingOesophageal Adenocarcinoma | Oesophageal Cancer | OESOPHAGO-GASTRIC CARCINOMA | Oesophageal Cancer Nos | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Oesophageal Junction Cancer | Breath Tests | Volatile Organic Compound
-
Medical Centre LeeuwardenUniversity of Groningen; LIMIS DevelopmentRecruiting
-
University of East AngliaCompletedOesophageal CancerUnited Kingdom
-
University Hospitals, LeicesterCompleted
-
Fiona ThistlethwaiteKarolinska University Hospital; University College London Hospitals; Erasmus... and other collaboratorsTerminated
-
Launceston General HospitalDepartment of Health, TasmaniaNot yet recruiting
Clinical Trials on Physical activity intervention group
-
University of Nove de JulhoUniversity of Sao PauloCompleted
-
University of MilanNot yet recruitingPreventing Age-Related Muscle Loss: the Role of Exercise in Improving Strength, Function, and Well-beingItaly
-
Universidade Estadual Paulista Júlio de Mesquita...University of SydneyUnknown
-
University of California, San FranciscoCompletedColon Cancer | Rectum CancerUnited States
-
University Hospitals, LeicesterLoughborough UniversityUnknownCardiovascular Diseases | Cardiovascular Risk Factor | COPDUnited Kingdom
-
University of Vic - Central University of CataloniaThe Social Services AdministrationCompletedPromotion of Healthy Eating Habits and Physical Activity Among Children and Their Families. (ALIAFF)Physical Activity | Children | Food Habits | FamiliesSpain
-
University of WashingtonArthritis FoundationRecruitingAxial SpondyloarthritisUnited States
-
University of Southern DenmarkTrygFonden, DenmarkUnknownObesity | Overweight | Metabolic Syndrome | ChildrenDenmark
-
Centro di Riferimento per l'Epidemiologia e la...Azienda Sanitaria Locale Torino 1CompletedBreast Cancer | Colorectal Cancer | Lifestyle Risk Reduction | Weight Changes, BodyItaly
-
Brown UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed